

| | | | | | | | | | | |
|----|----------------|-------------------|----------|------------------------------|------------------------------|-----|--------------------------|----------------|----------------|---|
| 21 | Katsarolis | 2010 2005-2006 | Grèce | Prospective | Communautaire | F | Cystite simple | Uro-pathogènes | 889 | FdR Cipro-R FIQ < 3 mois Aussi comparaison cystite simple VS IU compliquées |
| 22 | Kiffer | 2007 2000-2003 | Brésil | Prospective | Communautaire | H/F | Toutes | E. coli | 22679 | FdR FIQ-R Age > 60 ans |
| 23 | Killgore | 2004 2001-2001 | USA | Rétrospective Cas/Témoin | Communautaire | H/F | Toutes | E. coli | NS | FdR Cipro-R IU récidivantes, ttt antérieur par FIQ (délai?) |
| 24 | Labreche* | 2012 | USA | Monte Carlo | NS | NS | NS | NS | NS | Moins bonne réponse aux quinolones avec augmentation des résistances, pb pK/VPD |
| 25 | Lee | 2010 2006-2006 | Corée | Prospective | Communautaire | F | Cystite simple | E. coli | 225 | FdR Cipro-R Au moins 2 IU < 1 an |
| 26 | Lin | 2008 1999-1999 | Taiwan | Prospective Cas/Témoin | NS | H/F | Toutes | E. coli | 61-R 122-S | FdR Cipro-R Cathétérisme urinaire, ttt antérieur par FIQ (délai?) |
| 27 | Lobel | 2008 2003-2004 | France | NS | Comm + Noso | F | Toutes | E. coli | 1217 | FdR FIQ-R IU nosocomiale |
| 28 | Matsumoto | 2012 | Japon | NS | NS | F | Cystite | E. coli | NS | FdR FIQ-R Au moins 2 IU < 1 an, FIQ < 1 mois, déjà traité par AB pour la cystite actuelle |
| 29 | Mc Donald | 2001 1998-1998 | Taiwan | Prospective | Comm + Noso | H/F | Toutes + autres sites | E. coli | 1203 | FdR FIQ-R Infection nosocomiale, cancer |
| 30 | Meiland | 2004 1996-1998 | Pays-Bas | Prospective | Communautaire Diabétiques | F | BA | E. coli | 135 | Comparaison avec 5907 E. coli de F non diabétiques Diabète n'est pas un FdR de FIQ-R |
| 31 | Nicoletti | 2010 2006-2007 | Suisse | Cross-section | Comm + Noso | H/F | Toutes + BA | E. coli | 275 | FdR Cipro-R Cathétérisme urinaire, IU récidivantes, FIQ < 1 an |
| 32 | Olson | 2009 2005-2007 | USA | Rétrospective | Communautaire | F | Toutes | E. coli | 176 | FdR Cipro-R ATCD D'IU |
| 33 | Peterson | 2007 2004-2006 | USA | Post-hoc Analy Clin trial | Comm + Noso | H/F | IU compliquées PNA | Uro-pathogènes | 650 | FdR FIQ-R IU compliquée (versus PNA) |
| 34 | Rattanaumpawan | 2010 2003-2005 | USA | Cross-section | Nosocomial | H/F | Toutes | BGN | 251-R 263-S | FdR FIQ-R Homme, Afro-Américain, maladies respiratoire chronique long-séjour, hospit < 15 jours, hospit en médecine, ttt FIQ < 1 mois, ttt Bactrim < 1 mois, ttt Flagyl < 1 mois |
| 35 | Shigehara | 2009 2005-2008 | Japon | Rétrospective | Comm + Noso | H/F | Cystite compliquée | E. coli | 170 | FdR FIQ-R ttt FIQ < 1 mois, ttt FIQ < 3 mois, hospitalisation |
| 36 | Shin | 2012 2008-2008 | Corée | Rétrospective | NS | H/F | PNA simple | E. coli | 661 | Comparaison évolution FIQ-R vs FIQ-S Clinical cure moindre, durée de séjour plus longue |
| 37 | Smithson | 2012 | Espagne | Cross-section | Communautaire | H | Prostatite | E. coli | 153 | FdR FIQ-R IU liée aux soins (ATCD hospit, long-séjour, cathétérisme urinaire, geste uro invasif) ttt AB < 1 mois, ttt FIQ < 1 mois |
| 38 | Sotto | 2001 1998-1999 | France | Prospective | Comm + Noso | H/F | Toutes | E. coli | 320 | FdR FIQ-R Homme, IU < 1 an |
| 39 | Swami | 2012 2005-2009 | USA | Prospective | Comm + Noso | H/F | Toutes et BA | E. coli | 5619 | Incidence FIQ-R Augmente au cours du temps chez tous les adultes, mais surtout chez les > 80 ans |
| 40 | Talan | 2008 2000-2004 | USA | Prospective Cross-section | Communautaire | H/F | PNA | E. coli | 689 | Pas de conclusion sur FdR FIQ-R |

| | | | | | | | | | | |
|--|----------------|-------------------|---------------|---------------|---------------|-----|-----------------|----------------|---------------|---|
| 41 | Tassin | 2012 2010-2010 | France | Transversale | Comm + Noso | H/F | Toutes | Uro-pathogènes | 189 | Analyse sur les entérobactéries seules Oflo-R: pas de différence communautaire vs nosocomial ou lié aux soins |
| 42 | van der Starre | 2011 2004-2009 | Pays-Bas | Cas/Témoin | Communautaire | H/F | IU fébrile | E. coli | 51-R 369-S | FdR Cipro-R Cathétérisme urinaire, hospitalisation récente ttt FIQ < 6 mois |
| 43 | Vellinga | 2012 2009-2010 | Irlande | Prospective | Communautaire | H/F | Toutes | E. coli | 633 | FdR Cipro-R ttt par FIQ < 1 an (risque augmente avec 2 prescriptions ou plus versus 1 seule prescription) |
| 44 | Zhanel | 2006 2003-2004 | USA Canada | Prospective | Communautaire | H/F | Toutes et BA | E. coli | 1142 | FdR Cipro-R Age > 65 ans |
| 45 | Bedoin | 2014 2011-2012 | France | Rétrospective | Communautaire | F | PNA | E. coli | 344 | FdR FIQ-R FIQ<3mois, hospitalisation<6mois, insitutionnalisation |
| H/F: hommes/femmes, FdR: facteur de risque, Nal-R: résistance à l'acide nalidixique, Cipro-R: résistance à la ciprofloxacine, FIQ-R: résistance aux fluoroquinolones | | | | | | | | | | |
| BLSE: beta-lactamase à spectre étendu, NS: non spécifié, IU: infection urinaire, PNA: pyélonéphrite aiguë, BA: bactériurie asymptomatique | | | | | | | | | | |

Références Tableau bibliographique «Facteurs de risque de résistance aux fluoroquinolones»

1. Alós J-I, Serrano M-G, Gómez-Garcés J-L, Perianes J. Antibiotic resistance of *Escherichia coli* from community-acquired urinary tract infections in relation to demographic and clinical data. *Clin Microbiol Infect.* 2005 Mar;11(3):199–203.
2. Arslan H, Azap OK, Ergönül O, Timurkaynak F, Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among *Escherichia coli* strains isolated from community-acquired urinary tract infections in Turkey. *J Antimicrob Chemother.* 2005 Nov;56(5):914–8.
3. Blaettler L, Mertz D, Frei R, Elzi L, Widmer AF, Battegay M, et al. Secular Trend and Risk Factors for Antimicrobial Resistance in *Escherichia coli* Isolates in Switzerland 1997–2007. *Infection.* 2009 Nov 24;37(6):534–9.
4. Bolon MK, Wright SB, Gold HS, Carmeli Y. The Magnitude of the Association between Fluoroquinolone Use and Quinolone-Resistant *Escherichia coli* and *Klebsiella pneumoniae* May Be Lower than Previously Reported. *Antimicrobial Agents and Chemotherapy.* 2004 May 21;48(6):1934–40.
5. Boyd L, Atmar RL, Randall GL, Hamill RJ, Steffen D, Zechiedrich L. Increased fluoroquinolone resistance with time in *Escherichia coli* from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. *BMC Infect Dis.* 2008;8(1):4–7.
6. Bruyere F, Lanotte P, Faivre D'arcier B, Bou S, Haillet O. Les leçons à tirer d'un an de surveillance de *Escherichia coli* dans un service d'Urologie. *Progrès en Urologie.* 2007 Sep;17(5):964–7.
7. Cohen AE, Lautenbach E, Morales KH, Linkin DR. Fluoroquinolone-resistant *Escherichia coli* in the long-term care setting. *The American Journal of Medicine.* 2006 Nov;119(11):958–63.
8. Colodner R, Kometiani I, Chazan B, RAZ R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant *E. coli*. *Infection.* 2008 Feb;36(1):41–5.
9. Dromigny JA, Nabeth P, Juergens-Behr A, Perrier-Gros-Claude J-D. Risk factors for antibiotic-resistant *Escherichia coli* isolated from community-acquired urinary tract infections in Dakar, Senegal. *J Antimicrob Chemother.* 2005 Jun 7;56(1):236–9.
10. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant *Escherichia coli*. *J Urol.* 1995 Jan;153(1):117-20.
11. Eom J-S, Hwang B-Y, Sohn J-W, Kim W-J, Kim M-J, Park S-C, et al. Clinical and molecular epidemiology of quinolone-resistant *Escherichia coli* isolated from urinary tract infection. *Microb Drug Resist.* 2002;8(3):227–34.
12. Fabre R, Mérens A, Lefebvre F, Epifanoff G, Cerutti F, Pupin H, et al. Sensibilité aux antibiotiques des *Escherichia coli* isolés d'infections urinaires communautaires. *Médecine et Maladies Infectieuses.* 2010 Oct 1;40(10):555–9.
13. Gagliotti C, Nobilio L, Moro ML. Emergence of ciprofloxacin resistance in *Escherichia coli* isolates from outpatient urine samples. *Clinical Microbiology and Infection.* 2007 Feb 1;13(3):328–31.
14. Gagliotti C, Buttazzi R, Sforza S, Moro ML, Emilia-Romagna Antibiotic Resistance Study Group. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by *Escherichia coli*. *Journal of Infection* (2008) 57, 179-184
15. Gallini A, Degris E, Desplas M, Bourrel R, Archambaud M, Montastruc JL, et al. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant *Escherichia coli* in a university hospital. *J Antimicrob Chemother.* 2010 Dec;65(12):2650–7.
16. Gobernado M, Valdes L, Alós J-I, Garcia-Rey C, Dal-Re R, Garcia-de-Lomas J. Quinolone resistance in female outpatient urinary tract isolates of *Escherichia coli*: Age-related differences. *Revista Espanola de Quimioterapia.* 2007 Jul 20;20(2):206–10.
17. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial Resistance Among Uropathogens that Cause

- Community-Acquired Urinary Tract Infections in Women: A Nationwide Analysis. *Clin Infect Dis*. 2001 Jul;33(1):89–94.
18. Ha U-S, Kim ME, Kim CS, Shim BS, Han CH, Lee SD, et al. Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of disease. *International Journal of Antimicrobial Agents*. 2008 Feb;31 Suppl 1:S96–101.
19. Jeon JH, Kim K, Han WD, Song SH, Park KU, Rhee JE, et al. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by *Escherichia coli* in communities where the prevalence of fluoroquinolone resistance is high. *Antimicrobial Agents and Chemotherapy*. 2012 Jun;56(6):3043–6.
20. Kahan NR, Chinitz DP, Waitman DA, Dushnitzky D, Kahan E, Shapiro M. Empiric treatment of uncomplicated urinary tract infection with fluoroquinolones in older women in Israel: another lost treatment option? *Ann Pharmacother*. 2006 Dec;40(12):2223-7.
21. Katsarolis I, Poulakou G, Athanasia S, Kourea-Kremastinou J, Lambri N, Karaikos E, et al. Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment. *International Journal of Antimicrobial Agents*. 2010 Jan;35(1):62–7.
22. Kiffer CR, Mendes C, Oplustil CP, Sampaio JL. Antibiotic resistance and trend of urinary pathogens in general outpatients from a major urban city. *Int Braz J Urol*. 2007 Jan;33(1):42–8–discussion 49.
23. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant *Escherichia coli* urinary tract infection. *Ann Pharmacother*. 2004 Jul-Aug;38(7-8):1148-52.
24. Labreche MJ, Frei CR. Declining susceptibilities of gram-negative bacteria to the fluoroquinolones: effects on pharmacokinetics, pharmacodynamics, and clinical outcomes. *Am J Health Syst Pharm*. 2012 Nov 1;69(21):1863–70.
25. Lee G, Cho Y-H, Shim BS, Lee SD. Risk factors for antimicrobial resistance among the *Escherichia coli* strains isolated from Korean patients with acute uncomplicated cystitis: a prospective and nationwide study. *J Korean Med Sci*. 2010 Aug;25(8):1205–9.
26. Lin C-Y, Huang S-H, Chen T-C, Lu P-L, Lin W-R, Chen Y-H. Risk factors of ciprofloxacin resistance in urinary *Escherichia coli* isolates. *Journal of Microbiology, Immunology and Infection*. 2008 Aug;41(4):325–31.
27. Lobel B, Valot A, Cattoir V, Lemenand O, Gaillot O. Comparaison de la sensibilité aux antibiotiques de 1 217 isolats consécutifs de *Escherichia coli* responsables d'infections urinaires féminines en ville et à l'hôpital. *La Presse Médicale*. 2008 May;37(5):746–50.
28. Matsumoto T, Hamasuna R, Ishikawa K, Takahashi S, Yasuda M, Hayami H, et al. Sensitivities of major causative organisms isolated from patients with acute uncomplicated cystitis against various antibacterial agents: results of subanalysis based on the presence of menopause. *J Infect Chemother*. 2012 Aug;18(4):597–607.
29. McDonald LC, Chen FJ, Lo HJ, Yin HC, Lu PL, Huang CH, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in *Escherichia coli* in Taiwan and contributions of distinct selective pressures. *Antimicrobial Agents and Chemotherapy*. 2001 Nov;45(11):3084–91.
30. Meiland R, Geerlings SE, de Neeling AJ, Hoepelman AIM. Diabetes mellitus in itself is not a risk factor for antibiotic resistance in *Escherichia coli* isolated from patients with bacteriuria. *Diabetic Medicine*. 2004 Aug 18;21(9):1032–4.
31. Nicoletti J, Kuster SP, Sulser T, Zbinden R, Ruef C, Ledergerber B, et al. Risk factors for urinary tract infections due to ciprofloxacin-resistant *Escherichia coli* in a tertiary care urology department in Switzerland. *Swiss Med Wkly*. 2010;140:w13059.
32. Olson RP, Harrell LJ, Kaye KS. Antibiotic Resistance in Urinary Isolates of *Escherichia coli* from College Women with Urinary Tract Infections. *Antimicrobial Agents and Chemotherapy*. 2009 Feb 22;53(3):1285–6.
33. Peterson J, Kaul S, Khashab M, Fisher A, Kahn JB. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical

study in the United States from November 2004 through April 2006. *Clinical Therapeutics*. 2007 Oct;29(10):2215–21.

34. Rattanaumpawan P, Tolomeo P, Bilker WB, Fishman NO, Lautenbach E. Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections. *J Hosp Infect*. 2010 Dec;76(4):324–7.

35. Shigehara K, Uchibayashi T, Maeda E, Namiki M. Detection of drug-resistant *Escherichia coli* in patients with complicated cystitis: analysis of risk factors. *Int J Urol*. 2009 Oct;16(10):808–12.

36. Shin J, Kim J, Wie S-H, Cho YK, Lim SK, Shin SY, et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. *Microb Drug Resist*. 2012 Apr;18(2):169–75.

37. Smithson A, Chico C, Ramos J, Netto C, Sanchez M, Ruiz J, et al. Prevalence and risk factors for quinolone resistance among *Escherichia coli* strains isolated from males with community febrile urinary tract infection. *Eur J Clin Microbiol Infect Dis*. 2012 Jul 15;31(4):423–30.

38. Sotto A, De Boever CM, Fabbro-Peray P, Gouby A, Sirot D, Jourdan J. Risk factors for antibiotic-resistant *Escherichia coli* isolated from hospitalized patients with urinary tract infections: a prospective study. *Journal of Clinical Microbiology*. 2001 Feb;39(2):438–44.

39. Swami SK, Liesinger JT, Shah N, Baddour LM, Banerjee R. Incidence of Antibiotic-Resistant *Escherichia coli* Bacteriuria According to Age and Location of Onset: A Population-Based Study From Olmsted County, Minnesota. *Mayo Clin Proc*. 2012 Aug 1;87(8):753–9.

40. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ, EMERGENCY ID NET Study Group. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant *Escherichia coli* infection among emergency department patients with pyelonephritis. *Clin Infect Dis*. 2008 Nov 1;47(9):1150–8.

41. Tassain J, N'Guyen Y, Batalla A-S, Duval V, Guillard T, De Champs C, et al. Différences d'espèces en cause et de résistance aux fluoroquinolones des souches isolées dans les bactériuries selon leur caractère nosocomial, lié au soin ou communautaire. *Presse Med*. 2012 Dec;41(12 Pt 1):e586–93.

42. Van der Starre WE, van Nieuwkoop C, Paltansing S, Wout JWV, Groenveld GH, Becker MJ, et al. Risk factors for fluoroquinolone-resistant *Escherichia coli* in adults with community-onset febrile urinary tract infection. *Journal of Antimicrobial Chemotherapy*. 2011 Feb 9;66:650–6.

43. Vellinga A, Tansey S, Hanahoe B, Bennett K, Murphy AW, Cormican M. Trimethoprim and ciprofloxacin resistance and prescribing in urinary tract infection associated with *Escherichia coli*: a multilevel model. *J Antimicrob Chemother*. 2012 Oct;67(10):2523–30.

44. Zhanel GG, Hisanaga TL, Laing NM, Decorby MR, Nichol KA, Weshnoweski B, et al. Antibiotic resistance in *Escherichia coli* outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). *International Journal of Antimicrobial Agents*. 2006 Jun;27(6):468–75.

45. Bedoin M, Cazorla C, Lucht F, Berthelot P, Boyer M, Carricajo A, et al. Risk factors for quinolone-resistance in women presenting with *Escherichia coli* acute pyelonephritis. *Médecine et Maladies Infectieuses*. 2014 Apr 29.